[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349583-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349583-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","car-t-cell-therapy-potential-for-paediatric-brain-tumoursan-update","CAR-T cell therapy: potential for paediatric brain tumours—an update","","Central nervous system (CNS) tumours are the deadliest childhood cancers and current treatments remain limited. Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising option supported by encouraging clinical outcomes. Ongoing trials vary in delivery route, lymphodepletion, target antigen selection, and CAR engineering, and early learnings are needed. Key considerations include immunosuppressive tumour microenvironments, toxicities, CAR-T exhaustion, and tumour antigen heterogeneity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/car-t-cell-therapy-potential-for-paediatric-brain-tumoursan-update/349583/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/car-t-cell-therapy-potential-for-paediatric-brain-tumoursan-update/349583.png","ImageObject",300,407,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are paediatric CNS tumours difficult to treat?","Question",{"text":63,"@type":64},"They are highly lethal in children and existing therapy options are limited, with many histologies carrying poor prognosis. Treatment intensity can also create lifelong disability risks.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What variables differ across CAR-T clinical trials for paediatric CNS cancers?",{"text":68,"@type":64},"Trials differ by CAR-T delivery route, whether lymphodepletion is used, the identified target antigen, and CAR engineering features. These factors can influence effectiveness and safety.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges limit CAR-T performance in solid tumours?",{"text":72,"@type":64},"Immunosuppressive tumour microenvironments, toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity are highlighted. CAR design and manufacturing variables also affect the final product’s function.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349583,1790498539,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Neuro-Oncology (2026) 179:62 [https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1060-026-05604-5  \nREVIEW  \nCAR-T cell therapy: potential for paediatric brain tumours—an update  \nAlexandra Zehner1 · Benjamin Draper1 · Darren Hargrave1 · Laura K. Donovan1 · John Anderson1  \nReceived: 13 November 2025 / Accepted: 29 April 2026 © The Author(s) 2026  \nAbstract  \nCentral nervous system (CNS) tumours are the deadliest cancer for children and currently present limited treatment options. Chimeric antigen receptor (CAR)-T cell therapies have emerged as an innovative approach supported by encouraging clinical results. Current clinical trials using CAR-T cells in the treatment of paediatric CNS cancers differ in a number of variables, including the CAR-T cell route of delivery, presence of lymphodepletion, identified target antigen, and CAR engineering features. Considering early learnings across these areas is an essential step to developing more effective treatment options, especially given the challenges of immunosuppressive tumour microenvironments, various toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity. In sum, while there is a need for continued innovation, CAR-T cells represent a promising treatment approach for this devastating category of diseases.  \nKeywords Chimeric Antigen Receptor · CAR-T · Paediatric · CNS-tumour  \nIntroduction  \nCentral nervous system (CNS) tumours are the most prevalent solid cancer in the paediatric population [1], and within the past decade, have surpassed leukemia as the deadliest cancer for children 19 and younger [2] . This backdrop unwaveringly points to the necessity of innovative treatment options.  \nCurrently, limited therapy options exist for paediatric CNS tumours, with a dismal prognosis for many histologies. Standard approaches consist of surgery, radiation therapy, and chemotherapy. The intensity of these therapies, particularly when applied to a paediatric population,  \n John Anderson [j.anderson@ucl.ac.uk](j.anderson@ucl.ac.uk)  \nAlexandra Zehner  \n[a.zehner@ucl.ac.uk](a.zehner@ucl.ac.uk)  \nBenjamin Draper  \n[benjamin.draper@ucl.ac.uk](benjamin.draper@ucl.ac.uk)  \nDarren Hargrave  \n[d.hargrave@ucl.ac.uk](d.hargrave@ucl.ac.uk)  \nLaura K. Donovan  \n[l.k.donovan@ucl.ac.uk](l.k.donovan@ucl.ac.uk)  \n1 UCL Great Ormond Street Institute of Child Health, University College London, London, UK  \nconfers lifelong risk of severe disabilities. Immunotherapy in the form of checkpoint inhibitors [3, 4] and vaccine studies [5] has emerged as an exciting therapeutic opportunity but shown limited efficacy in this disease setting. Monoclonal antibodies have also shown limited benefit; for example, I-8H9 radioimmunotherapy targeting B7-H3 has been extensively investigated with no clear evidence of efficacy [6] . However, as targeted approaches offer exciting potential to reach precarious structures while limiting off-target toxicity, additional immunotherapy avenues are worth pursuing, including chimeric antigen receptor (CAR)-T cell therapies (Fig. 1) .  \nTo develop CAR-T cells, endogenous T cells are taken from a patient and modified to recognize an antigen of interest. After expansion, they are infused back into the patient to identify the antigenic target and initiate an immune response [8] (Fig. 2) . A breakthrough for treating haematological malignancies, it has proven difficult to extend encouraging CAR-T cell results to solid tumours. Among the challenges include immunosuppressive tumour microenvironments, various toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity. Many variables in CAR design and method of manufacturing impact on the functioning of the final product. Of particular relevance are the number and nature of costimulation domains, the respective number of CD4 and CD8 cells in the product, and the length and cytokine milieu of manufacturing expansion [9] .  \nFig. 1 Second generation CAR. Second-generation CARs consist of four domains: a","cbCaiegEFtFygBX6","https://ap.wps.com/l/cbCaiegEFtFygBX6","pdf",2359894,17,"English","# Abstract\n## Introduction\n## CAR-T cell design and manufacturing\n## Clinical trial evidence in paediatric CNS tumours","[{\"question\":\"Why are paediatric CNS tumours difficult to treat?\",\"answer\":\"They are highly lethal in children and existing therapy options are limited, with many histologies carrying poor prognosis. Treatment intensity can also create lifelong disability risks.\"},{\"question\":\"What variables differ across CAR-T clinical trials for paediatric CNS cancers?\",\"answer\":\"Trials differ by CAR-T delivery route, whether lymphodepletion is used, the identified target antigen, and CAR engineering features. These factors can influence effectiveness and safety.\"},{\"question\":\"What challenges limit CAR-T performance in solid tumours?\",\"answer\":\"Immunosuppressive tumour microenvironments, toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity are highlighted. CAR design and manufacturing variables also affect the final product’s function.\"}]","CAR-T cell therapy: potential for paediatric brain tumours—an update | PDF",1790084429,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cc1a2ceaeb33a94784b86ed18c089b3.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e7405c1bbc79d09eb1884a0b64502f6.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94bccc7bd576f63d1bf9edea330abbc8.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e739ce77c32a286af450e4c7e4543f1.webp",980,1301]